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Transvenous extractionThe implantation rate of cardiac rhythm devices, such as
permanent pacemakers and implantable cardioverter-deﬁbrilla-
tors, has increased signiﬁcantly over the past decades. Owing to
this increase, there is a growing rate of transvenous lead extraction
(TLE) due to lead failure, device infection, device upgrading, and
lead or device recalls. However, TLE is a complex, invasive, and
challenging procedure. The troubleshooting experience in opera-
tors and the multidisciplinary team formation are determinants of
procedural outcome.
The necessity of TLE is divided practically into two cases, i.e.
case of device or pocket infection and that of non-infection. The
circumstance of non-infection includes malfunctioning, upgrading,
or recalled lead or device. RiataTM (St. Jude Medical, St. Paul, MN,
USA) and Sprint Fidelis1 (Medtronic Inc, Minneapolis, MN, USA)
leads were recalled by the US Food and Drug Administration due to
an increased rate of failure [1]. There is still a controversy
concerning the management of failed, unnecessary, recalled, or
redundant leads. Reportedly, the factors inﬂuencing the physi-
cians’ decision-making of TLE are the patients’ age, the presence of
damaged leads, and lead dwelling time, according to the European
EP Wire survey conducted by the European Heart Rhythm
Association [2]. The decision-making and procedural outcomes
are dependent also on the volume of the extraction referral centers
[3].
On the other hand, the situation is different in the case of lead,
device, or pocket infection, because such infections may be fatal
and it requires intensive antibiotic therapy and total system
removal. In this issue of the Journal of Cardiology Cases, Kypta et al.
report an interesting case of a 47-year-old female who had
undergone tricuspid mechanical valve replacement followed by
dual chamber pacemaker implantation due to postoperative
complete atrioventricular block. The permanent pacemaker had
to be replaced because of battery depletion. She was referred to
their institution for TLE because of evident pocket infection [4]. The
REPLACE study has demonstrated that cases of device revision or
lead addition within a short period of time have high risk ofDOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.10.011
http://dx.doi.org/10.1016/j.jccase.2015.11.003
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsprocedure-related infection [5]. These results indicate that careful
decision-making and long-term perspective were required in the
pacemaker-dependent patients with drug abuse, as in this case
when repetitive pacemaker revision and tricuspid valve surgery
were performed.
The Heart Rhythm Society/European Heart Rhythm Associa-
tion (EHRA) Guideline recommends complete lead and device
removal [6,7] in the case of pocket infection (Class 1), as in this
case evidenced by swab test proven positive for Staphylococcus
epidermidis [4]. The guideline includes the principles for infected
system removal followed by later contralateral implantation of a
new system (Class 1) associated with intensive and appropriate
antibiotic therapy. However, simultaneous removal of infected
system and implantation of a new system is required occasionally
in pacemaker-dependent patients. Amraoui et al. compared the
outcomes of delayed transvenous implantation of pacemaker on
the opposite site with those of immediate surgical epicardial
approach in pacemaker-dependent patients undergoing TLE due
to device infection [8]. They concluded that there were equivalent
outcomes between the two approaches. However, therapeutic
strategy is complicated particularly in the pacemaker-dependent
patients undergoing mechanical tricuspid valve replacement. To
avoid right ventricular (RV) pacemaker lead trapping, authors
postulated three options, i.e. (1) minimally invasive left-sided
epicardial leads and device implantation, (2) a coronary sinus
(CS) and new right atrial (RA) leads placement associated with a
new device on the opposite site, (3) temporary CS pacing followed
by a new system implantation at opposite side (two-step
approach). Option 1 is a high-risk procedure in this patient
undergoing several open-chest surgeries. The same is true in
option 3 considering fatal temporary CS lead dislodgement. The
remaining option 2 requires the CS lead placement at the same
session as infected system removal in this pacemaker-dependent
case.
A potential proarrhythmic effect has been raised in biventri-
cular pacing using RV and CS leads for heart failure patients
[9]. This is partly due to inhomogeneous repolarization caused by
focal epicardial activation [10]. Since ventricular transmural
excitation propagates from endocardium to epicardium, CS pacing
opposes to this physiological activation sequence. Importantly,
authors found in this case that QTc interval recorded by single-site
pacing at either anterior or posterolateral vein is longer than that
recorded by dual-site CS pacing via anterior and lateral veins.
Although the reason for this phenomenon is speculative, possible
hemodynamic improvement obtained by the dual-site pacing may
have abbreviated QRS duration and hence QTc interval. Paced QTc reserved.
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pacemaker patients than the intrinsic QTc interval [11]. In this
sense, it is appreciated that the authors strived for minimizing the
QTc interval by choosing the dual-site CS pacing modality and
seeking the optimal target vein.
In summary, Kypta et al. present a suggestive and rare case of
TLE. As opposed to recommendation of the guideline, they
performed a one-step procedure of infected system removal and
a contralateral new device implantation using two CS leads due
partly to lack of decision-making tools in such a complicated case.
Empirical decision-making of TLE in pacemaker-dependent
patients with tricuspid mechanical valve may be reﬁned in the
near future according to the evolution of sophisticated lead
extraction techniques and new pacemaker technology, i.e. TLE
using excimer laser sheath is available in Japan since 2009, and
permanent leadless pacemakers of NanostimTM (St. Jude Medical,
Sylmar, CA, USA) and MicraTM (Medtronic Inc.) have entered
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